1. Phair J, Muoz A, Detel R, et al.The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1.Multicenter AIDS Cohort Study Group.N Engl J Med, 1990, 322:161-165.
[2]
3. Furrer H, Egger M, Opravil M, et al.Discontinuation of primary maIy prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy.Swiss HIV Cohort Study.N Engl J Med, 1999, 340:1301-1306.
[3]
4. CatherinotI E, Lanternier F, Bougnoux ME, et al.Pneumocystis jirovecii pneumonia.Infect Dis Clin North Am, 2010, 24:107-138.
11. Esteves F, Lee GH, de Sousa B, et al.(1-3)-Beta-D-glucan in association with lactate dehydrogenase as biomarkers of Pneumocystis pneumonia(Pcp) in HIV-infected patients.Eur J Clin Microbiol Infect Dis, 2014, 33:1173-1180.
[8]
12. 李宏军.中国艾滋病影像学研究现状与临床应用.磁共振成像, 2010, 1:346-348.
[9]
13. Hardak E, Brook O, Yigla M.Radiological features of Pneumocystis jirovecii pneumonia in immunocompromised patients with and without AIDS.Lung, 2010, 188:159-163.
10. Boldt MJ, Bai TR.Utility of lactate dehydrogenase vs radiographic severity in the differential diagnosis of Pneumocystis jirovecii pneumonia.Chest, 1997, 111:1187-1192.
17. Roembke F, Heinzow1 HS, Gosseling T.Clinical outcome and predictors of survival in patients with pneumocystis jirovecii pneumonia-results of a tertiary referral centre.Clin Respir J, 2014, 8:86-92.